Who Should Not Take GLP-1 Medication? Clinical Contraindications

Last reviewed: May 18, 2026

Last updated: May 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 medications are not suitable for everyone. Patients with personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, severe pancreatitis, or uncontrolled diabetes should avoid these medications. A thorough medical evaluation determines individual eligibility.

Understanding who should not take GLP-1 medications protects patient safety and ensures treatment aligns with medical history. PlexusDx emphasizes precision screening, combining clinical assessment with genetic insights into peptide metabolism pathways to support provider decision-making.

Absolute Contraindications: When GLP-1 Medications Are Not Safe

Absolute contraindications represent conditions where GLP-1 use carries unacceptable risk. Personal or family history of medullary thyroid carcinoma (MTC) is a black-box warning across all GLP-1 drugs. Multiple endocrine neoplasia type 2 (MEN 2) also contraindicates GLP-1 therapy due to MTC risk.

Severe diabetic retinopathy with macular edema may worsen with rapid glucose lowering in type 2 diabetes. Acute pancreatitis or history of recurrent pancreatitis contraindicates GLP-1 use. Patients with thyroid cancer or undiagnosed thyroid nodules require endocrinologist clearance before starting.

Clinical Risk Factors Requiring Provider Evaluation and Monitoring

Beyond absolute contraindications, several risk factors warrant careful provider assessment. These conditions increase adverse event risk but may not completely exclude GLP-1 therapy—rather, they require baseline testing, dose adjustment, and close monitoring during treatment initiation and titration.

Risk assessment combines medical history with current medications and comorbidities. Genetic predisposition in peptide signaling pathways can also provide context for how individual patients metabolize and respond to GLP-1 medications, supporting more tailored clinical decisions.

Clinical Condition or Risk Factor	Clinical Consideration and Monitoring Need
History of thyroid cancer or nodules	Requires baseline ultrasound and endocrinologist clearance; GLP-1 use contraindicated in medullary thyroid carcinoma
Severe renal impairment (eGFR <15)	Dose adjustment or avoidance may be necessary; limited safety data in advanced kidney disease
History of pancreatitis (acute or chronic)	Increased risk of recurrence; requires amylase/lipase baseline; close symptom monitoring essential
Diabetic retinopathy with macular edema	Rapid glucose lowering may worsen edema; ophthalmology consultation recommended before GLP-1 initiation
Gastroparesis or severe GI motility disorder	GLP-1 slows gastric emptying; may exacerbate symptoms; provider assessment needed
Uncontrolled type 2 diabetes (HbA1c >10%)	Rapid glucose change risk; requires careful titration and frequent monitoring
Dehydration risk or hypovolemia	GLP-1-induced nausea increases dehydration risk; fluid intake counseling essential
Concurrent use of insulin or sulfonylureas	Hypoglycemia risk increases; dose adjustment of other agents required

Medication Interactions and Polypharmacy Considerations

GLP-1 medications interact with other drugs, particularly those affecting glucose metabolism. Insulin and sulfonylureas increase hypoglycemia risk when combined with GLP-1 therapy; dose reduction of these agents is often necessary. ACE inhibitors and ARBs require monitoring for blood pressure and renal function changes.

Oral medications including certain antibiotic classes and immunosuppressants may have delayed absorption due to GLP-1-induced gastric slowing. Patients taking multiple cardiovascular medications require baseline assessment and periodic review. Genetic variation in drug-metabolizing enzymes may influence medication interactions for individual patients.

Special Populations: Age, Pregnancy, and Genetic Predisposition

GLP-1 medications are not recommended during pregnancy or breastfeeding due to limited safety data. Women of childbearing age should use effective contraception during treatment. Older adults may require dose adjustment and more frequent monitoring, particularly those with multiple comorbidities or polypharmacy.

Genetic predisposition in GLP-1 receptor pathways, GIPR signaling, and MC4R function influences individual metabolic response. PlexusDx's Precision Peptide Genetic Test can reveal variants that may support provider discussion about dosing strategy, but genetic predisposition does not independently contraindicate therapy—it informs personalization and monitoring intensity.

Provider Assessment Framework: When to Defer or Avoid GLP-1 Therapy

Qualified healthcare providers use structured clinical assessment to determine GLP-1 eligibility. Essential baseline evaluations include thyroid function, amylase and lipase levels, renal function, and imaging if history of thyroid disease exists. Blood pressure and volume status require documentation before initiating therapy.

Patients should disclose complete medical history, all medications, and family history of cancer or endocrine disease before starting GLP-1 treatment. Provider expertise in metabolic medicine and understanding of individual risk stratification ensures safe treatment decisions. Shared decision-making between patient and provider, informed by clinical evidence and personalized data, yields the best outcomes.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that understanding individual peptide metabolism pathways may help provide context for GLP-1 eligibility and response. The Precision Peptide Genetic Test examines variants in GLP1R, GIPR, FTO, and MC4R genes—markers that may reveal predisposition to metabolic response patterns. This genetic context should be interpreted with a qualified healthcare provider and does not replace clinical screening or medical evaluation.

Genetic variants identified by the Precision Peptide Genetic Test can support a more personalized conversation with your provider about whether GLP-1 therapy aligns with your individual metabolic profile. These predispositions do not predict exact medication response or determine candidacy alone—medical history, contraindications, and current health status remain the primary determinants of safety and eligibility.

If you're considering GLP-1 medication and have risk factors or questions about contraindications, a provider-supervised assessment combined with genetic insight can guide more informed decisions. PlexusDx compounded GLP-1 options are available through licensed 503A pharmacies once a provider determines you are a suitable candidate and establishes a dosing plan tailored to your health profile.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.